Alert

Recommended Alerts

Sign Up For Alerts

New SACHRP Recommendations on Interactions among Sponsors, Clinical Trial Sites, and Study Subjects

The U.S. Department of Health and Human Services Secretary’s Advisory Committee on Human Research Protections (“SACHRP”) recently issued recommendations on interactions between clinical trial sponsors (which could be either industry or academic entities) and clinical trial subjects. Increased interactions between sponsors and patient populations have begun to blur the traditional division of roles between sponsors and investigators. SACHRP’s recommendations contemplate such changes in the clinical trial enterprise, examine the key legal and ethical concerns in this area, and offer specific solutions for addressing these challenges.

Read More

Drug Pricing: What Happened in 2019 and What to Watch in 2020

Practices: Health Care, Life Sciences, Drug Pricing & Price Reporting

Printer-Friendly Version

Have you heard that drug prices are too high? If not, you have not been listening to President Donald Trump, Secretary of Health and Human Services (“HHS”) Alex Azar, or almost any member of Congress. In the past year, a dizzying array of drug pricing actions and proposals have come out of the White House and Congress, as well as the governor’s offices and legislative halls in most states.

Click here to read the full Alert.

Printer-Friendly Version

Cookie Settings